Objective: Describe the surgical technique, complications, and long-term outcomes of total pancreatectomy and islet autotransplantation (TP-IAT) in a large series of pediatric patients. Background: Surgical management of childhood pancreatitis is not clear; partial resection or drainage procedures often provide transient pain relief, but long-term recurrence is common due to the diffuse involvement of the pancreas. Total pancreatectomy (TP) removes the source of the pain, whereas islet autotransplantation (IAT) potentially can prevent or minimize TP-related diabetes. Methods: Retrospective review of 75 children undergoing TP-IAT for chronic pancreatitis who had failed medical, endoscopic, or surgical treatment between 1989 and 2012. Results: Pancreatitis pain and the severity of pain statistically improved in 90% of patients after TP-IAT (P < 0.001). The relief from narcotics was sustained. Of the 75 patients undergoing TP-IAT, 31 (41.3%) achieved insulin independence. Younger age (P = 0.032), lack of prior Puestow procedure (P = 0.018), lower body surface area (P = 0.048), higher islet equivalents (IEQ) per kilogram body weight (P = 0.001), and total IEQ (100,000) (P = 0.004) were associated with insulin independence. By multivariate analysis, 3 factors were associated with insulin independence after TP-IAT: (1) male sex, (2) lower body surface area, and (3) higher total IEQ per kilogram body weight. Total IEQ (100,000) was the single factor most strongly associated with insulin independence (odds ratio = 2.62; P < 0.001). Conclusions: Total pancreatectomy and islet autotransplantation provides sustained pain relief and improved quality of life. The β-cell function is dependent on islet yield. Total pancreatectomy and islet autotransplantation is an effective therapy for children with painful pancreatitis that failed medical and/or endoscopic management.
tially with elevation of serum amylase and lipase, and with imaging of acute and/or chronic pancreatitis. The disease is usually progressive, with recurrent hospitalizations, increasing pain and narcotic dependence, loss of school days, and impaired quality of life. In these cases, progression to exocrine and endocrine insufficiency is common; in addition, lifetime risk of pancreatic adenocarcinoma is elevated. 2, 3 Initial treatment is directed at relieving pain and restoring quality of life; treatments include narcotic analgesics, pancreatic enzymes to reduce pancreatic stimulation and treat pancreatic exocrine insufficiency, nerve block procedures such as celiac plexus blocks, and endoscopic decompression by pancreatic sphincterotomy, stone extraction, stricture dilation, and stent placement. [4] [5] [6] Those who fail these medical and endoscopic interventions may be candidates for surgical intervention.
The role of surgical management for pediatric patients with CP is not clear. A number of surgical techniques have been used in an attempt to ameliorate pain and restore quality of life, including partial resection, or drainage procedures such as lateral pancreaticojejunostomy (such as Puestow), or variants (such as Frey, Beger procedures). 7, 8 Patients often have transient pain relief, but due to the diffuse nature and involvement of the entire pancreas, pain eventually recurs in up to 50% of patients [9] [10] [11] [12] [13] [14] ; exocrine and endocrine insufficiency often develops over time. 15 Total pancreatectomy (TP) removes the source of the pain and potentially eliminates risk of pancreatic cancer. However, when used in isolation, TP results in brittle diabetes, and as a result, it is rarely done as a first procedure in children with CP.
In 1977, a novel approach was developed for treatment of CP in adults: TP, and isolation and autotransplantation of the patient's islets (TP--islet autotransplantation TP-IAT). 16 The goal of the islet autotransplantation was to prevent or minimize TP-related diabetes. Since then, there have been several reports of TP-IAT in the adult population [17] [18] [19] [20] [21] [22] [23] [24] ; however, there have been limited reports in children. 25, 26 We report techniques, complications, and long-term outcomes of TP-IAT in a large series of pediatric patients. inability to participate in ordinary activities, repeated hospitalizations, or constant need for narcotics, each coupled with failure to respond to maximal medical treatment or endoscopic pancreatic duct drainage procedures. In addition, there must be objective findings of CP, including at least 1 of the following: (1) pancreas calcifications on computed tomographic scan, or abnormal endoscopic retrograde cholangiopancreatography, or 6 of 9 criteria or more on endoscopic ultrasound; or (2) any 2 of following 3: (1) ductal or parenchymal abnormalities on secretin-stimulated magnetic resonance cholangiopancreatography, endoscopic ultrasound of pancreas with 6 of 9 criteria positive, or abnormal pancreatic function tests with peak bicarbonate less than 80 mmol/L; or (2) histopathologic confirmed diagnosis of CP from previous operations; or (3) hereditary pancreatitis (PRSS1 gene mutation, SPINK1 gene mutation, CFTR gene mutations), with a compatible clinical history; or (4) history of recurrent acute pancreatitis with more than 3 episodes of pain associated with imaging diagnostic of acute pancreatitis and/or elevated serum amylase or lipase 3 times normal. 17 This study was approved by the University of Minnesota Institutional Review Board. Informed consent and assent were obtained from parents and patients for all patients participating in quality of life assessments.
Surgical Technique
The main variation in the surgical technique for children receiving an IAT is preserving the blood supply to the pancreas until the dissection is completed for resection, thus minimizing the warm ischemia time and maximizing islet cell preservation. In addition, important surgical steps in the pediatric patient include special attention to avoid any inadvertent injury or spasm of the small vessels to pancreas, pylorus preservation, and use of a Roux-en-Y loop for duodenojejunostomy to minimize postoperative gastrointestinal complications such as bile reflux gastritis. For the procedure, we use a midline incision, as it is associated with less pain than in a bilateral subcostal incision. After opening the abdominal cavity, and performing any necessary adhesion lysis, a Kocher maneuver is performed to completely mobilize the duodenum and the pancreatic head until the left renal vein and the superior mesenteric artery are well visualized. The peritoneum on the anterior surface of the portal triad is opened; the gastroduodenal artery is dissected and looped. Papaverine (1%) is sprayed on the artery to prevent spasm. The short gastric vessels are divided; the spleen is mobilized by dividing the splenorenal and splenocolic ligaments. Using the spleen as a handle, the tail and the body of the pancreas are mobilized all the way medially to the level of the superior mesenteric vein. The fibrofatty tissue around the splenic artery and the splenic vein both anteriorly in the front and behind are dissected and splenic artery is identified and looped on the superior border of the pancreas. The splenic vein is looped distal to the entry of the inferior mesenteric vein. The duodenum is transected 3 cm distal to the pylorus using a GIA stapler (1 proximate, reloadable linear cutter stapler 55 mm, Ethicon Endosurgery, NJ). The right gastric and gastroepiploic blood vessels are preserved and the stomach is reflected upward and laterally to expose the head and body of the pancreas. The distal duodenum is transected at the ligament of Treitz. Superior mesenteric vein is identified and carefully dissected. The pancreatic neck is elevated off the portal vein. The bile duct is identified and transected at the superior border of the pancreas. Careful examination is done to look for any accessory right hepatic artery arising from the superior mesenteric artery. If one exists, it is carefully preserved. The uncinate process of the pancreas is mobilized off the portal vein by dividing all the small tributaries to the portal vein. At this stage, the pancreas is connected only by its vascular structures, and the islet cell isolation team is alerted.
The vascular structures are divided in the following order: gastroduodenal artery, splenic artery, and splenic vein. The pancreas is then immediately placed in cold sterile preservative solution and transported to the islet isolation laboratory. While the processing of the pancreas is continued in the laboratory, gastrointestinal reconstruction in initiated as follows: the proximal jejunum is mobilized and brought into the infrahepatic region on the right side. A choledochojejunostomy in end-to-side (end of bile duct to the side of jejunum) is constructed using multiple interrupted absorbable sutures. Twenty centimeters downstream, the jejunum is divided using a GIA a stapler. A 40-cm Roux-en-Y limb is fashioned. A duodenal jejunostomy is constructed in an end-to-side fashion in 2 layers using multiple absorbable interrupted sutures. A gastrojejunostomy tube is placed in the stomach using the Stamm technique and the tip of the jejunal tube placed in the distal jejunum. The entire procedure lasted 9.8 ± 1.1 hours, including the islet preparation time of 4.8 ± 0.1 hours.
Islet Isolation
Our islet isolation technique is described elsewhere. 17, [27] [28] [29] For the pediatric pancreata, we currently use a new enzyme mixture that consists of a higher proportion of intact C1:C2 clostridium histolyticum (Ch) collagenase, and Ch neutral protease. The new enzyme mixture improved islet yields in pediatric pancreata without compromising their functional capacity in vivo. 27, 28 Although the pancreas size was smaller in children, we have consistently obtained high islet yield per gram pancreas in children compared with adults. 27, 28 Currently, if the postdigest tissue volume of tissue is less than 0.25 mL/kg, the islet cells are considered purified.
Islet Cell Infusion
Before starting islet infusion, the patient is given 70 units per kilogram of heparin, and the heparin is allowed to circulate for at least 3 minutes. The islet product also contains 30 units per kilogram of heparin. The patient is also started on dextran 0.5 cc per kilogram to a maximum of 10 cc per hour continuous infusion. Dextran specifically inhibits the extrinsic pathway of coagulation. The splenic vein stump or the middle colic pain is cannulated and attached to pressure tubing with an in-line manometer, which is typically zeroed before starting the infusion. The islet preparation is infused by gravity into the portal vein system. Baseline portal pressure is first recorded and the pressure is measured every 3 minutes. If the pressure increases to greater than 25 cm of saline, infusion is paused for 15 minutes and the pressure measured. Most of the time, there is autoregulation and the portal pressure decreases. It is important to closely monitor pressures changes at 3-minute intervals in children. If the pressure is less than 25 cm saline, the infusion is restarted. If the pressure is more than 25 cm saline (after waiting for 15 minutes to autoregulate), or if a total tissue volume of 0.25 mL/kg, the portal infusion is stopped and the rest of the islet preparation is implanted in the peritoneal cavity as a thin film. The total time spent on infusing islets ranged from 60 to 110 minutes.
Postoperative Management
All patients are started on an insulin drip to maintain blood glucose control between 80 and 120 mg/dL in the immediate postoperative period to relieve β-cell functional stress during islet engraftment. [30] [31] [32] [33] The portal vein is evaluated by Doppler ultrasound on postoperative days 1 and 7. Dextran 40 is continued for 48 hours, after which aspirin 2 mg/kg is started. The heparin drip is continued at 10 units per kilogram for 7 days. If the Doppler ultrasound revealed any portal vein clots, anticoagulation with warfarin is continued for 3 months.
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Delayed gastric emptying is common in the early postoperative period, requiring gastric decompression via the gastric port of the gastrojejunal tube (placed in the operating room) to decompress the stomach and simultaneously give jejunal feeds. As soon as the small bowel ileus resolves, enteral feeding is started through the jejunal port of the tube. A polymeric formula appropriate for the age of the child is used with pancreatic enzymes supplied in the tube feeding. Oral diet is started as the delayed gastric emptying resolves and is evident by low gastrostomy tube outputs. Platelet counts were checked every other day, and if the count was more than 10 6 /mm 3 , hydroxyurea 500 mg orally twice a day is initiated.
Postoperative Follow-up
During the first 3 months post-TP-IAT, nearly all patients receive exogenous insulin to relieve β-cell functional stress during the engraftment (neovascularization) stage. [30] [31] [32] [33] Thereafter, insulin is weaned as long as blood glucose levels remain in a near normal target range (fasting <125 mg/dL, postprandial <180 mg/dL, and glycosylated hemoglobin ≤6.5%). If these parameters were not achieved, the patients were maintained on insulin.
Diet is advanced and tube feeds are stopped when the patient was able to take adequate oral calories and protein. Patients are seen after surgery in outpatient clinics at 3 months, 6 months, and 1 year, and thereafter annually. Routine laboratory studies are obtained at these intervals, including fasting glucose and C-peptide, stimulated glucose and C-peptide, and hemoglobin A 1c level for assessment of metabolic control and islet graft function.
Management of Exocrine Pancreatic Insufficiency
When weaned to oral feeds, all patients are educated on the use of pancreatic enzymes, with a recommended initial dose of 1000 lipase units/kg/meal (half for snacks) and a goal dose of 1500 lipase units/kg/meal. All patients are started on a fat-soluble vitamin supplement (SourceCF or AquaAdek). Fat-soluble vitamin levels and B 12 levels are monitored at 3 months, 6 months, and 1 year after surgery, and then yearly. All patients meet with our dietician at each visit and receive counseling regarding a low oxalate diet to prevent kidney stones. Weight and height are measured and monitored at each visit to assess adequacy of pancreatic enzyme replacement.
Splenectomy Management
All patients have splenectomy as part of the TP-IAT. All children are fully immunized against Haemophilus influenzae type b, meningococcus, and pneumococcus. Vaccination is completed at least 2 weeks before splenectomy. All children are maintained on prophylactic antibiotics for 1 year, and all patients and their parents receive counseling regarding the risks and management of splenectomy.
Pain Management
All patients were on narcotics before the operation. Patients are postoperatively started on intravenous narcotics, and as they resume gastrointestinal function, oral narcotics are started. Patients are weaned off narcotics in the outpatient clinics.
Data Review
For the 75 patients having TP-IAT, medical records were reviewed and clinical data prospectively stored in a long-term autoislet database analyzed. We studied surgical complications, narcotic use before and after the procedure, short-and long-term success of the islet transplantation, and postoperative quality of life. For the analysis of factors predicting insulin independence, we included 58 patients, who had sufficient long-term follow-up (>1 year), to attain insulin independence and excluded the remaining 17 patients from analysis. Narcotic use was determined from the medical records and from self-reported survey data. Patients were classified as either being on narcotics (no matter the dose) or off narcotics, meaning that they took no narcotics daily or intermittently. Patients were asked whether they had any pain during follow-up and whether any component of the pain was similar to what they considered pancreatic pain similar to the time before TP-IAT.
Quality of Life Assessments
Beginning in 2007, quality of life surveys were administered to patients undergoing TP-IAT (n = 30). 25 Patients (families) were asked to complete a comprehensive survey before surgery and at 3, 6, and 12 months and annually after surgery. The RAND Medical Outcomes Study 36-Item Short Form Health Survey was used as a measure of generic health-related quality of life. Additional survey items included questions about school attendance, pain symptoms, narcotic use, and insulin requirements. 25 Parents were asked to report whether CP kept their child from attending school and for the number of limited activity days during the past 28 days.
Statistical Analysis
Continuous variables were summarized as means and standard errors of the mean. Categorical variables were summarized as counts and percents. All analyses were performed using SAS/STAT 9.2 software (SAS Institute Inc, Cary, NC). The prevalence of pain was assessed for (1) pancreatitis pain and (2) the severity of pain. Assessments were made pretransplant and post-TP-IAT at 1 month, 6 months, 1 year, and annually thereafter. Trajectory of changes were evaluated using either generalized linear mixed models for categorical outcomes or general linear mixed models for continuous variables. Global tests for a difference in prevalence and pain severity over time were tested using a type III test for fixed effect of time. The underlying variance structure for both approaches used compound symmetry. Changes from pretransplant were evaluated by examining change scores at each point-in-time after TP-IAT.
For the analysis, patients were classified as follows: (1) insulinindependent, (2) partial graft function [C-peptide positive defined as >0.6 ng/dL or C-peptide unknown, the ability to maintain near normal glucose and glycohemoglobin levels on once daily long-acting insulin only or with only occasional supplementation (less than daily) with short-acting insulin], or (3) insulin-dependent [C-peptide <0.6 ng/mL; or if unknown on both long-and short-acting insulin (basalbolus regimen) to maintain glycemic control. 17 Individual patient classifications as to islet function could change over time. For example, an insulin-independent patient could revert to partial graft function or insulin dependence; or, an insulin-dependent could attain partial function or if partial function, could change to either of the other categories. The rate of insulin independence was evaluated using Kaplan-Meier, time-to-event analysis. For this analysis, the number of months to insulin independence was depicted as a cumulative incidence function. The likelihood of becoming insulin independent was evaluated using multivariate logistic regression. Bivariate analyses were used to screen possible risk factors for inclusion in a multivariate adjusted model for insulin independence. We excluded the later 17 patients in our series from the analysis, and these patients by definition lacked the follow-up or length of time after the islet transplant time necessary for patients to attain insulin independence. Recipient characteristics separately statistically associated with insulin independence were included in a full model and evaluated as independent risk factors. Multivariate logistic regression was used to construct the final adjusted model. In constructing the model, forward stepwise and backward stepwise regression was used to arrive at a parsimonious list of factors for inclusion in the final model. A final, reduced multivariate model was based on risk factors that were statistically associated with insulin independence at 5% level of significance.
Patients and Demographics
A total of 75 TP-IATs were done in 75 pediatric patients. Of these, 11 had a previous procedure and underwent completion pancreatectomy and 64 had 1-stage TP ( Table 1) . Baseline demographic characteristics at the time of TP-IAT are presented in Table 1 . By etiology of CP, the idiopathic/familial/genetic constituted the majority.
Previous Treatment Given to the Patients
Of the 75 patients, all patients had failed medical treatment and endoscopic therapy or were not amenable to endoscopic treatment due to anatomical considerations or failed surgical treatment or progressive hereditary disease. The previous surgical procedures performed are listed in Table 2 .
Surgical and All Cause of Mortality
There was 1 in-hospital mortality (1.3%). The cause of death was sepsis resulting from enteric perforation due to a feeding tube placed in the operating room. In addition, there were 2 late deaths unrelated to TP-IAT. One patient had an infection of a paraspinal rod placed for scoliosis 4 years before TP-IAT; she died of acute respiratory distress syndrome associated with paraspinal infection 7 years after TP-IAT. At the time of death, she was pain free and insulin independent. The second patient died 8 years after TP-IAT, a sudden death due to sepsis, at an outside emergency room, and an autopsy was not performed. In both the cases, we were unable to obtain the culture reports from the treating facility to ascertain the causative infection. Since these 2 deaths, we have instituted postsplenectomy prophylaxis in all our patients .The median follow-up was 3.86 years (range: 0.6-23.49 years; interquartile range: 6.09 years).
Surgical Complications
Surgical complications occurred in 15 (20%) of patients ( Table 3 ). The complication rate was significantly lower in younger (<12 years) children (P = 0.041).
Intra-abdominal bleeding occurred in 4 patients, all of whom had high postislet cell infusion portal pressures (>25 mm Hg). Postsplenectomy thrombocytosis (>10 6 /mm 3 ) occurred in 30 (40%) 
Pain and Narcotic Use
All patients were on narcotics before TP-IAT ( Fig. 1) . Figure 2 gives the prevalence of pain at each point-in-time after TP-IAT. Pancreatitis pain and the severity of pain statistically improved over time (P ≤ 0.001) after TP-IAT. Nearly all improvement in pancreatitis pain occurred in the first 3 months after TP-IAT (Fig. 2) . Figure 1 shows that except for the first month after TP-IAT, narcotic use was statistically reduced after TP-IAT. Much of this decline occurs in the first year after surgery and remains relatively constant at between 10% and 20% from the first year after TP-IAT forward. The relief from narcotics is sustained (Fig. 1 ).
Insulin Use and Islet Cell Function
Of the 75 patients having TP-IAT, 31 (41.3%) achieved insulin independence ( Fig. 3 ). Time to insulin independence is displayed in Figure 3 . Twenty-eight of the 31 patients achieved insulin independence within 12 months after TP-IAT. Younger children (<12 years) were more likely to achieve insulin independence than older children (P = 0.05) ( Fig. 4) .
Insulin independence has been observed for as long as 10 years after TP-IAT ( Fig. 5 ). Complete follow-up data on islet cell function at intervals of 6 months, 1 year, 2 years, and 3 years were available for 49 patients. The proportion of patients with insulin independence, partial graft function, and insulin dependence over the first 3 years postoperatively is shown in Table 4 . Mean ± SEM hemoglobin A 1c level for the entire cohort regardless of graft function was 6.88 ± 2.4% at 1 year, 5.8 ± 0.55% at 3 years, and 5.7 ± 0.52% at 5 years. All insulin-independent patients are confirmed or presumed to be C-peptide positive. Mean ± SEM stimulated C-peptide in insulinindependent/partial graft function patients was 2.21 ± 1.43 ng/mL, 3.38 ± 1.89 ng/mL, and 2.85 ± 0.07 ng/mL at 1 year, 3 years, and 5 years, respectively.
Of the 31 patients who attained insulin independence, 3 reverted to insulin dependence [partial graft function ( Fig. 5) ]. The clinical details were as follows:
Case 1 is a 9-year-old girl with an unusual underlying diagnosis of Goldston syndrome (renal cysts + Dandy-Walker malformation and in her case, pancreatic cysts with pancreatitis), with developmental delay and feeding and motility issues. She received an islet mass of 148,907 higher islet equivalents (IEQ), in her case 6053 IEQ per kilogram, and was initially insulin independent. However, about 1.5 years post-TP-IAT, she was admitted for motility evaluation and enteral feed initiation at an outside hospital, where she had a precipitating event of Escherichia coli bacteremia that was associated with sudden and severe hyperglycemia. She had a documented HbA 1c level of 5.8% and measured glucoses 70 to 116 mg/dL only 4 days before the onset of bacteremia, confirming that this patient had normoglycemia off insulin before infection. With E. coli infection, initial glucose on day of infection onset was first documented at 328 mg/dL and then remained 216 to 428 mg/dL until hospital discharge. Hyperglycemia was inadequately treated and not communicated to our institution until after patient's discharge, 10 days after event, at which time glucoses remained frequently more than 200 mg/dL during tube feeding, and we initiated basal insulin coverage. The patient remained with partial graft function at last follow-up. We believe that the patient had suffered partial loss of islet mass because of sustained hyperglycemia in this case. Case 2 is a 13-year-old adolescent boy with history of a prior Puestow procedure and the first pediatric case in the series. He received 3100 IEQ per kilogram, was off insulin therapy with HbA 1c low to mid-6% range, until HbA 1c elevated to 7% at nearly 2 years postoperatively and insulin was initiated. This case had a lower than average islet mass and using our current protocols, might have been maintained on basal insulin therapy because of borderline HbA 1c . Case 3 is an 11-year-old boy with severe PRSS1 disease who received only 1926 IEQ per kilogram at the time of transplant. Despite low islet mass, he weaned off insulin entirely and maintained normal HbA 1c (multiple documented levels <6%) until 3 years after TP-IAT. At that time, his HbA 1c elevated to 6.7%, with modest hyperglycemia detected by home meter and insulin was resumed. At that time, islet mass had decreased to about 1300 IEQ per kilogram.
Factors Predicting Insulin Independence
For the 58 patients with adequate long-term follow-up to allow for insulin independence (>12 months), younger age (P = 0.032), no prior Puestow procedure (P = 0.018), lower body surface area (P = 0.048), higher IEQ per kilogram body weight (P = 0.001), and total IEQ transplanted (100,000) (0.004) were associated with a higher probability of insulin independence ( Table 5 ). Using multivariate logistic regression, 3 factors were associated with a higher probability of insulin independence after TP-IAT (Table 6 ): (1) male sex, (2) lower body surface area, and (3) total IEQ transplanted. Total IEQ given in units of 100,000 is by far and away the single factor most strongly associated with insulin independence (odds ratio = 2.62; P < 0.001). The odds of insulin independence in boys are nearly 17 times greater than those in girls. Increased body surface area is associated with a decreased likelihood of insulin independence, suggesting that body surface area is a proxy for patient age, which was associated with independence in the unadjusted analysis. Overall, the statistics for final multivariate-adjusted logistic regression model support good discrimination and calibration.
Quality of Life Data
Ninety-two quality of life surveys were completed by 30 recipients. Completion rate was 97% at baseline and 60% to 81% at any time point after surgery. Responses to the 36-Item Short Form Health Survey among those 12 years of age and older show a statistical improvement in physical and mental health after TP-IAT using mixed model methods. The Physical Component Summary Scale score improved with time (P = 0.007), changing from pretransplant by nearly 2 standard deviations (17.2 points). The Mental Component Summary Scale was similarly improved (P = 0.024). The mental component of the health status score improved by more than 2 standard deviations (22.2 points). Significant improvements were seen in all 8 subscales, with the most dramatic improvements in raw score for role-physical (14 ± 7 at baseline vs 83 ± 10 at 1 year, P < 0.001) and bodily pain (25 ± 5 at baseline vs 70 ± 7 at 1 year, P < 0.001). Figure 6 shows that the percentage of parents reporting their condition kept them from attending school. Based on a generalized linear mixed model, the percentage of parents reporting lost days at school statistically declined (P < 0.001). Pre-TP-IAT, 87% of the parents reported lost school days compared with a negligible value at 2 years. The number of limited activities showed a similar statistical decline over the same period (P < 0.001). The number of limited activity days at 24 months was about 20% of what was reported pre-TP-IAT ( Fig. 6 ).
DISCUSSION
The primary goal of surgical treatment of childhood CP is to relieve pain and restore quality of life. Although many different operative procedures short of TP have been performed for CP, and pain is ameliorated initially, it recurs in more than 50% of patients. [9] [10] [11] [12] [13] [14] Total pancreatectomy potentially eliminates the source of pain but results in brittle diabetes that can be difficult to treat, hence the addition of IAT. The first TP-IAT in a child was reported in 1996, done with the goal of eliminating pain and minimizing postsurgical diabetes. 26 Our current data in 75 children demonstrate that there is sustained pain relief, acceptable long-term glycemic control, and improved quality of life after TP-IAT. Operative morbidity in our series was low compared with literature reports of TP for other indications. 34 The surgical complication rate was 20%; most complications were relatively minor and none had long-term sequelae. Younger children (<12 years) tended to have a lower complication rate, perhaps due to shorter duration of illness. An important observation from our series is that the addition of islet autotransplantation to TP did not increase the morbidity associated with TP alone. Unlike the adult series, we have routinely measured the portal pressure at 3-minute intervals during islet cell infusion 12 because of concern about the possibility of development of portal vein thrombosis. We did not continue infusion if portal pressure reached 25 cm of saline. We feel that beyond this threshold there is an increased risk of bleeding and thrombosis. 35 All 4 patients who had intra-abdominal bleeding had pressures greater than 25 mm Hg. The maximum amount of islet cell infused intraportal in our series is 0.25 mL/Kg. If infusion was stopped because of elevated portal pressure, the remainder of the islets were placed in the peritoneal cavity. Although we have used this site, we do not have data to document the degree of engraftment at this site as opposed to the intrahepatic site of islet cell implantation.
Prior pancreatic surgery has significant impact on outcomes of TP-IAT. Previous surgery did not increase the surgical complication rate; however, prior Puestow operation resulted in a significantly lower islet yield and increased the risk of insulin dependence in long-term follow-up. Timing of the TP-IAT is likely a very important consideration as well. Younger children had a lower surgical complication rate and a higher chance of insulin independence. We believe that children with the PRSS1 mutations and other forms of progressive hereditary pancreatitis are best served by TP-IAT performed earlier due to impaired quality of life, progressive destruction of islet cells, and increased lifetime risk of cancer. Of those with the PRSS1 genetic mutations, the association between CP and cancer has been well established. Over time, the risk approaches 40%. 2 There is a theoretical risk of cancer developing with IAT, but to date, in our entire series of 75 patients, none have developed any malignancy.
Although we have no method to directly measure islet mass, and thus cannot definitively comment on whether transplanted islet mass grows with time in children, our data suggest some ability of the transplanted islet mass to compensate appropriately with growth of the child. This is most striking in our youngest children, who have the greatest growth potential. In our cohort, among the children aged 5 to 9 years at transplant with more than 2 years of follow-up for growth, there were 8 children with long-term insulin independence (2.5-8 years, n = 7) or long-term minimal insulin use (2 units/d × 13 years, n = 1), who maintained this insulin independence (or low insulin requirement in the latter case) despite significant growth. These 8 children underwent transplantation at a mean age of 8.0 ± 1.7 years, most recently aged 14.6 ± 3.5 years. As expected, during this time of rapid growth, significant weight gain was observed, from 29 ± 9 kg to 51 ± 15 kg, and the relative islet mass for body size (calculated on the basis of the number of islets transplanted) was reduced by 42%, from 6325 ± 3816 IEQ per kilogram at transplant to 3661 ± 2873 IEQ per kilogram at follow-up.
This series includes two 5-year-olds, 6 and 8 years post-TP-IAT, both maintaining insulin independence despite change in calculated islet mass per kilogram body weight from 6362 IEQ per kilogram to 3406 IEQ per kilogram in the first case (now an 11-yearold girl) and 10,647 IEQ per kilogram to 3066 IEQ per kilogram in the second case (now a 14-year-old teenage boy). Thus, we believe that the data are optimistic in regard to the potential for compensatory growth in islet mass over time. Although β-cell replication is mostly limited to infancy and early childhood, children in this young age group (younger than 10 years) have been demonstrated to have increased capacity for β-cell replication compared with adolescents and adults on autopsy studies. 36 We have also demonstrated previously a capacity for neogenesis of islet-like structures from ductal cells in the young patients with severe pancreatitis, suggesting that ductal precursors transplanted in the "impure" fractions of the islet preparation could also theoretically provide a precursor for islet mass in these younger patients. 37 Insulin independence is clearly dependent on the number of islets transplanted. Although our numbers are too small to clearly determine a breakpoint, our data suggest that children who receive more than 2500 IEQ per kilogram are more likely to achieve insulin independence. Importantly, even the children who have partial function and need some insulin on a daily basis have improved quality of life compared with their pre TP-IAT status.
CONCLUSIONS
In summary, we present a large surgical series of islet autotransplantation in children. Total pancreatectomy and autoislet cell transplant provide sustained pain relief and improved quality of life in the majority of children with chronic painful pancreatitis who fail medical and/or endoscopic treatment.
